Avadel Pharmaceuticals plc AVDL
Updated: 16 Jun 2026
No signal published yet
We already track Avadel Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Avadel Pharmaceuticals plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Avadel Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On February 12, 2026, Alkermes plc announced the completion of its acquisition of Avadel Pharmaceuticals for approximately $2.1 billion. Following the merger, Avadel's ordinary shares were delisted from the Nasdaq Stock Market. The acquisition integrates Avadel's flagship narcolepsy treatment into Alkermes' neuroscience portfolio.
What Firelda Watch includes for Avadel Pharmaceuticals plc
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Avadel Pharmaceuticals plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Avadel Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more